HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.

Abstract
We have investigated dihydropyrimidine dehydrogenase expression as a prognostic marker in breast cancer. A total of 119 women with breast cancer undergoing surgery between 1985 and 1996 were included in this study. Eighty-seven patients were treated with postoperative chemotherapy including 5-fluorouracil or 5-fluorouracil derivatives. Fifty-nine (50%) of 119 patients were determined to be immunostaining-positive for dihydropyrimidine dehydrogenase. There was no significant difference between dihydropyrimidine dehydrogenase staining and tumour size, lymph node status, clinical stage, oestrogen receptor status, histologic grade, or 5-fluorouracil administration. When evaluated in patients treated with 5-fluorouracil or 5-fluorouracil derivatives, patients with dihydropyrimidine dehydrogenase-positive tumours had a significantly (P<0.05) poorer disease-free survival compared to those with dihydropyrimidine dehydrogenase-negative tumour. No conclusion can be drawn about the prognostic impact of dihydropyrimidine dehydrogenase status in patients who were not treated with 5-fluorouracil regimes due to the small number of such cases in this series. Lymph node and dihydropyrimidine dehydrogenase status were independent prognostic factors for disease-free survival, and lymph node status for overall survival using multivariate analysis. In conclusion, dihydropyrimidine dehydrogenase is a possible prognostic factor in patients with breast cancer treated with 5-fluorouracil or 5-fluorouracil derivatives.
AuthorsJ Horiguchi, H Takei, Y Koibuchi, K Iijima, J Ninomiya, K Uchida, R Ochiai, M Yoshida, T Yokoe, Y Iino, Y Morishita
JournalBritish journal of cancer (Br J Cancer) Vol. 86 Issue 2 Pg. 222-5 (Jan 21 2002) ISSN: 0007-0920 [Print] England
PMID11870510 (Publication Type: Journal Article)
CopyrightCopyright 2002 The Cancer Research Campaign
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Oxidoreductases
  • Dihydrouracil Dehydrogenase (NADP)
  • Fluorouracil
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor
  • Breast Neoplasms (drug therapy, enzymology, pathology)
  • Chemotherapy, Adjuvant
  • Dihydrouracil Dehydrogenase (NADP)
  • Disease-Free Survival
  • Female
  • Fluorouracil (administration & dosage)
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Staging
  • Oxidoreductases (biosynthesis)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: